Mini-dose weekly adriamycin therapy for patients with advanced malignant disease at increased risk for adriamycin toxicity

A. Kessinger, H. M. Lemon, J. F. Foley

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In an effort to administer adriamycin safely to patients with advanced progressive malignant disease and an increased risk for adriamycin toxicity, a weekly schedule of 10-20 mg of intravenous adriamycin was used for 38 patients. All patients had been previously treated with chemotherapy and/or radiation therapy. These patients also had advanced age (8), liver disease (8), previous radiation to the myocardium (18), prior bone marrow depression (21), concurrent bone marrow depression (9) and/or were intolerant to usual adriamycin dosages (2). Five patients had an objective remission and eight had disease stabilization. Toxicity was not eliminated; 39% had leukopenia (WBC<3,500); four had alopecia; nausea and vomiting forced one to stop therapy; extravasation occurred in three; vaginitis occurred in one; one had diarrhea; and one had an arrhythmia. One patient died a septic death during a leukopenic phase. Adriamycin can be given to poor-risk patients on a weekly basis using mini-doses, but severe toxicity cannot be avoided at these dosages.

Original languageEnglish (US)
Pages (from-to)113-115
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume6
Issue number1
DOIs
StatePublished - Jan 1 1983

Fingerprint

Doxorubicin
Therapeutics
Bone Marrow
Vaginitis
Alopecia
Leukopenia
Nausea
Vomiting
Liver Diseases
Cardiac Arrhythmias
Diarrhea
Myocardium
Appointments and Schedules
Radiotherapy
Radiation
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mini-dose weekly adriamycin therapy for patients with advanced malignant disease at increased risk for adriamycin toxicity. / Kessinger, A.; Lemon, H. M.; Foley, J. F.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 6, No. 1, 01.01.1983, p. 113-115.

Research output: Contribution to journalArticle

@article{6e4cc6fe65bf4fdd906a1e90269e216e,
title = "Mini-dose weekly adriamycin therapy for patients with advanced malignant disease at increased risk for adriamycin toxicity",
abstract = "In an effort to administer adriamycin safely to patients with advanced progressive malignant disease and an increased risk for adriamycin toxicity, a weekly schedule of 10-20 mg of intravenous adriamycin was used for 38 patients. All patients had been previously treated with chemotherapy and/or radiation therapy. These patients also had advanced age (8), liver disease (8), previous radiation to the myocardium (18), prior bone marrow depression (21), concurrent bone marrow depression (9) and/or were intolerant to usual adriamycin dosages (2). Five patients had an objective remission and eight had disease stabilization. Toxicity was not eliminated; 39{\%} had leukopenia (WBC<3,500); four had alopecia; nausea and vomiting forced one to stop therapy; extravasation occurred in three; vaginitis occurred in one; one had diarrhea; and one had an arrhythmia. One patient died a septic death during a leukopenic phase. Adriamycin can be given to poor-risk patients on a weekly basis using mini-doses, but severe toxicity cannot be avoided at these dosages.",
author = "A. Kessinger and Lemon, {H. M.} and Foley, {J. F.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1097/00000421-198302000-00019",
language = "English (US)",
volume = "6",
pages = "113--115",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Mini-dose weekly adriamycin therapy for patients with advanced malignant disease at increased risk for adriamycin toxicity

AU - Kessinger, A.

AU - Lemon, H. M.

AU - Foley, J. F.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - In an effort to administer adriamycin safely to patients with advanced progressive malignant disease and an increased risk for adriamycin toxicity, a weekly schedule of 10-20 mg of intravenous adriamycin was used for 38 patients. All patients had been previously treated with chemotherapy and/or radiation therapy. These patients also had advanced age (8), liver disease (8), previous radiation to the myocardium (18), prior bone marrow depression (21), concurrent bone marrow depression (9) and/or were intolerant to usual adriamycin dosages (2). Five patients had an objective remission and eight had disease stabilization. Toxicity was not eliminated; 39% had leukopenia (WBC<3,500); four had alopecia; nausea and vomiting forced one to stop therapy; extravasation occurred in three; vaginitis occurred in one; one had diarrhea; and one had an arrhythmia. One patient died a septic death during a leukopenic phase. Adriamycin can be given to poor-risk patients on a weekly basis using mini-doses, but severe toxicity cannot be avoided at these dosages.

AB - In an effort to administer adriamycin safely to patients with advanced progressive malignant disease and an increased risk for adriamycin toxicity, a weekly schedule of 10-20 mg of intravenous adriamycin was used for 38 patients. All patients had been previously treated with chemotherapy and/or radiation therapy. These patients also had advanced age (8), liver disease (8), previous radiation to the myocardium (18), prior bone marrow depression (21), concurrent bone marrow depression (9) and/or were intolerant to usual adriamycin dosages (2). Five patients had an objective remission and eight had disease stabilization. Toxicity was not eliminated; 39% had leukopenia (WBC<3,500); four had alopecia; nausea and vomiting forced one to stop therapy; extravasation occurred in three; vaginitis occurred in one; one had diarrhea; and one had an arrhythmia. One patient died a septic death during a leukopenic phase. Adriamycin can be given to poor-risk patients on a weekly basis using mini-doses, but severe toxicity cannot be avoided at these dosages.

UR - http://www.scopus.com/inward/record.url?scp=0020595519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020595519&partnerID=8YFLogxK

U2 - 10.1097/00000421-198302000-00019

DO - 10.1097/00000421-198302000-00019

M3 - Article

C2 - 6837502

AN - SCOPUS:0020595519

VL - 6

SP - 113

EP - 115

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -